Decheng Capital

Ottimo Pharma specializes in developing innovative cancer therapies for solid tumors. Its primary focus is Jankistomig, a bi-functional antibody that targets both immune checkpoint inhibition and angiogenesis, two key pathways involved in cancer growth. By simultaneously addressing these pathways, Ottimo Pharma's approach offers healthcare professionals a dual-pronged strategy to potentially enhance treatment outcomes and reduce the burden of cancer on patients and the healthcare system.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative therapies for dermatological and immuno-inflammatory conditions. Founded by the creators of Vicept Therapeutics, the company is dedicated to addressing significant unmet needs in these fields, focusing on areas where no FDA-approved treatments exist or where treatment options are limited. Aclaris operates primarily in two segments: therapeutics and contract research. The therapeutics segment is engaged in the identification and development of novel drug candidates, while the contract research segment generates revenue through laboratory services. Among its developmental candidates is Zunsemetinib, an oral MK2 inhibitor aimed at treating immuno-inflammatory diseases.

Medtech Technology is a firm that develops innovative ophthalmic medical devices.It has developed its own artificial lens production and research technology platform, as well as a technological barrier to high-end artificial lens manufacture.

FireFly Bio focuses on developing Degrader Antibody Conjugates (DACs), a novel approach that merges the benefits of antibody-drug conjugates with selective protein degraders. This proprietary healthcare platform is designed to enhance cancer treatment by ensuring the precise delivery of therapeutic agents to targeted tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create more effective and targeted medicines that improve patient outcomes in the fight against cancer.

Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.

Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, and innovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.

LEADRIVE is a technology company specializing in the research, development, production, and sales of drive solutions for new energy vehicles, as well as high-performance power semiconductor modules. The company designs and manufactures advanced motor controllers and proprietary power modules that have been adopted by over ten leading automotive manufacturers and Tier-1 suppliers for mass production. LEADRIVE is also engaged in enhancing the localization of power semiconductor modules, with ongoing certification processes for silicon carbide modules and electronic controls. Additionally, the company invests in innovative energy solutions, including wind, solar, and energy storage systems. In collaboration with Rohm Semiconductor from Japan, LEADRIVE has established a joint laboratory to develop various silicon carbide modules, focusing on improving efficiency through comprehensive simulation, testing, and development processes that span from device-level to vehicle-level applications.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.

Cellares Corporation, founded in 2019 and based in South San Francisco, California, focuses on advancing cell therapy for cancer treatment by addressing the significant manufacturing challenges associated with these therapies. The company has developed the Cell Shuttle, an automated and closed end-to-end manufacturing solution designed to enhance the scalability and efficiency of cell therapy production. This innovative system allows for the simultaneous production of multiple patient doses, achieving tenfold scalability compared to traditional methods, while also reducing process failure rates by three times and lowering manufacturing costs by up to 70 percent. Cellares aims to make life-saving cell therapies more affordable and widely accessible to patients in need, thereby accelerating the development and availability of these critical treatments.

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

VintaBio specializes in providing contract development and manufacturing services for cell and gene therapies, focusing on the production of viral vectors. The company addresses the challenges associated with the viral vector bottleneck in the development of cell and gene therapies. VintaBio offers customized process development, ensuring compliance with Good Manufacturing Practices (GMP) from the proof of concept stage through to clinical trials and biologics license applications. By producing both GMP-grade and research-grade viral vectors, VintaBio supports pharmaceutical companies and molecular biologists in their efforts to deliver genetic material into cells effectively and efficiently.

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.

LevitasBio is focused on advancing cellular analytics through its innovative magnetic levitation technology. This platform, known as LeviCell, allows for the label-free purification of cells and nuclei, enabling researchers to analyze biological signatures without altering or damaging the samples. By overcoming traditional limitations in cellular analysis, LevitasBio's approach facilitates the study of high-value primary samples and sensitive cell types, regardless of their initial conditions. This capability provides significant advantages for scientists in the life sciences and healthcare sectors, allowing for a deeper and more accurate understanding of biological processes.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, and innovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease.

Watchmaker Genomics, Inc. is a biotechnology company focused on advancing the applications of DNA reading, writing, and editing. Based in Boulder, Colorado, the company specializes in protein engineering and enzyme manufacturing, which are critical for meeting the quality and performance demands of various genomics applications. By providing scalable supply chain solutions, Watchmaker Genomics enhances genomic experiments, assays, and workflows for its clients. Founded in 2018 and originally known as Alpha Catalyst Genomics, Inc., the company rebranded in July 2019 to better reflect its mission in the genomic landscape.

Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Mirvie is a biotech company focused on developing non-invasive tests aimed at improving maternal-fetal health. Founded in 2018 and based in South San Francisco, California, Mirvie offers a medical diagnostic platform that provides actionable insights for mothers and families throughout their pregnancy journey. The company's innovative predictive tests help medical practitioners identify at-risk pregnancies, allowing for timely interventions and enhanced management of pregnancy-related concerns. By prioritizing safety and health, Mirvie seeks to empower families with the information necessary for better pregnancy outcomes.

USCI Medical Laboratory is a national high-tech company specializing in genetic testing services, particularly in tumor diagnosis and eugenics gene sequencing. The laboratory focuses on developing integrated diagnostic equipment and clinical processes that enhance bioinformatics and minimize diagnostic errors. Its capabilities include batch sample detection, mass data analysis, and advanced gene sequencing technologies. USCI Medical Laboratory is committed to providing comprehensive medical health solutions that encompass disease prevention, prediction, detection, interpretation, and intervention, thereby advancing the field of genomic disease screening and prevention.

Nalu Medical is an early-stage company based in Carlsbad, California, specializing in the development of innovative medical devices aimed at alleviating chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator designed for neurostimulation, which has received FDA clearance for both spinal cord stimulation and peripheral nerve stimulation. By focusing on neuromodulation, Nalu Medical offers a diverse range of therapeutic options, enabling patients to receive effective treatments that improve their quality of life.

Solve Therapeutics is a biopharmaceutical company based in Belmont, California, founded in 2021. The company specializes in the development of first-in-class antibody-drug conjugates and bispecific therapeutics. With a team of experienced professionals, Solve Therapeutics aims to create innovative biopharmaceutical medicines that address significant unmet medical needs, ultimately enhancing patient outcomes and quality of life.

ImmPACT Bio USA Inc. is a cell therapy company focused on developing engineered T-cells specifically designed to target and treat solid tumors. By utilizing advanced technology, the company aims to create chimeric antigen receptor (CAR) T-cell therapies that exhibit tumor specificity, allowing them to induce cytotoxicity only when interacting with tumor cells while sparing healthy tissues. This selective targeting mitigates the safety risks commonly associated with existing CAR-T therapies, providing a promising approach to cancer treatment that enhances efficacy and reduces potential harm to noncancerous cells.

Kind Pharmaceutical is a clinical-stage biopharmaceutical company that focuses on the discovery and development of anemia drugs. The company was founded in 2013 and is headquartered in Redwood City, California, United States.

Acelyrin is a late-stage clinical biopharmaceutical company dedicated to advancing new treatment options for patients. The company specializes in identifying, acquiring, and accelerating the development and commercialization of promising drug candidates. By leveraging its expertise, Acelyrin aims to rapidly bring transformative medicines to market, ultimately improving patient outcomes and quality of life.

Haoxinqing is an online medical service platform specializing in mental psychology and chronic disease management. The platform offers users remote diagnosis and treatment services, allowing patients to access medical care conveniently from their homes. By focusing on these areas, Haoxinqing aims to improve the accessibility and quality of healthcare for individuals dealing with mental health issues and chronic conditions.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

Shape Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Seattle, Washington. The company specializes in RNA-editing gene therapy targeting neurodegenerative disorders, oncology, metabolic conditions, and rare genetic diseases. Its proprietary RNAfix technology enables precise editing of RNA using the body's natural cellular mechanisms, which minimizes risks associated with immunogenicity, cellular toxicity, and off-target DNA editing. Shape Therapeutics employs a comprehensive approach to RNA gene therapy, integrating innovative payload, delivery, and manufacturing platform technologies. This strategy aims to facilitate the development of effective treatments and potential cures for a wide range of diseases, with the goal of enhancing patient outcomes across the healthcare landscape.

GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.

Adela specializes in developing advanced technologies for the early detection of cancer and other serious health conditions through routine blood tests. The company's genome-wide methylome enrichment platform efficiently captures comprehensive data from the entire methylome, enabling the identification of highly informative methylated regions of the genome. This targeted approach facilitates the detection and classification of tumors using plasma cell-free DNA methylomes. Adela's innovations not only aid in cancer detection but also extend to prenatal diagnostics, cardiology, and the monitoring of immune responses, thereby enhancing overall healthcare outcomes.

Xtremity is focused on developing innovative prosthetic technology aimed at improving the mobility of amputees. The company has created a medical device that features advanced polymer materials, which facilitate quicker fittings and easy adjustments for prosthetic sockets. These sockets are designed to be easily moldable, extremely durable, and compatible with a variety of suspension systems. By reducing the need for multiple appointments, Xtremity's customizable sockets empower users to regain their independence and enhance their quality of life.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Cellares Corporation, founded in 2019 and based in South San Francisco, California, focuses on advancing cell therapy for cancer treatment by addressing the significant manufacturing challenges associated with these therapies. The company has developed the Cell Shuttle, an automated and closed end-to-end manufacturing solution designed to enhance the scalability and efficiency of cell therapy production. This innovative system allows for the simultaneous production of multiple patient doses, achieving tenfold scalability compared to traditional methods, while also reducing process failure rates by three times and lowering manufacturing costs by up to 70 percent. Cellares aims to make life-saving cell therapies more affordable and widely accessible to patients in need, thereby accelerating the development and availability of these critical treatments.

PackGene Biotech, LLC is a biotechnology company based in the United States that specializes in developing viral vectors for gene therapies. It primarily focuses on adeno-associated virus (AAV) vectors, offering comprehensive services that include vector design, cloning, and packaging. The company also provides solutions for mRNA, plasmid DNA, and lentiviral vectors. With an emphasis on early-stage drug discovery and preclinical development, PackGene Biotech supports researchers in the medical industry by delivering high-purity, high-titer, and high-infectivity vectors for clinical applications. Its capabilities enable scalable and cost-effective production, facilitating advancements in cell and gene therapy trials.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Equillium Inc is a biotechnology company focused on developing innovative therapies for autoimmune and inflammatory disorders that have significant unmet medical needs. The company's leading product candidate, EQ001, is a first-in-class monoclonal antibody that specifically targets the immune checkpoint receptor CD6, which is crucial in regulating effector T cell activity associated with various immuno-inflammatory diseases, including graft-versus-host disease, asthma, uveitis, colitis, lupus, and multiple sclerosis. In addition to EQ001, Equillium's pipeline includes itolizumab, an antibody targeting the CD6-ALCAM pathway, which is undergoing Phase 3 trials for acute graft-versus-host disease and Phase 1b trials for lupus nephritis. The company is also advancing EQ101, a cytokine inhibitor aimed at IL-2, IL-9, and IL-15, which is poised to enter Phase 2 studies for alopecia areata, and EQ102, another cytokine inhibitor that targets IL-15 and IL-21, which is ready for clinical development.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, focused on discovering and developing therapeutics for unmet medical needs, particularly in respiratory viral infections and viral hepatitis. Founded in 2013, the company is dedicated to addressing global health challenges with its innovative products, which include AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences aims to establish itself as a leader in antiviral drug development through a commitment to scientific excellence and innovation.

LevitasBio is focused on advancing cellular analytics through its innovative magnetic levitation technology. This platform, known as LeviCell, allows for the label-free purification of cells and nuclei, enabling researchers to analyze biological signatures without altering or damaging the samples. By overcoming traditional limitations in cellular analysis, LevitasBio's approach facilitates the study of high-value primary samples and sensitive cell types, regardless of their initial conditions. This capability provides significant advantages for scientists in the life sciences and healthcare sectors, allowing for a deeper and more accurate understanding of biological processes.

Encodia, Inc., founded in 2015 and headquartered in San Diego, California, specializes in proteomics research and the development of innovative protein analysis technology. The company offers a platform that utilizes reverse-translation technology to convert peptide sequence information into DNA libraries, facilitating scalable and efficient protein sequencing. This capability enables researchers to analyze protein samples comprehensively, thereby advancing the field of personalized medicine. By democratizing access to detailed information on cellular processes, Encodia aims to accelerate the discovery of novel approaches to addressing challenging diseases.

GRIT Biotechnology is a research and development company based in Shanghai, China, focusing on tumor infiltration lymphocytes (TIL) immunotherapy for the treatment of solid tumors. Founded in 2019, the company is dedicated to advancing the field of immunotherapy with the aim of enhancing the effectiveness of tumor treatments. By leveraging innovative approaches in TIL technology, GRIT Biotechnology seeks to provide new therapeutic options for patients battling solid tumors.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

PackGene Biotech, LLC is a biotechnology company based in the United States that specializes in developing viral vectors for gene therapies. It primarily focuses on adeno-associated virus (AAV) vectors, offering comprehensive services that include vector design, cloning, and packaging. The company also provides solutions for mRNA, plasmid DNA, and lentiviral vectors. With an emphasis on early-stage drug discovery and preclinical development, PackGene Biotech supports researchers in the medical industry by delivering high-purity, high-titer, and high-infectivity vectors for clinical applications. Its capabilities enable scalable and cost-effective production, facilitating advancements in cell and gene therapy trials.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, focused on discovering and developing therapeutics for unmet medical needs, particularly in respiratory viral infections and viral hepatitis. Founded in 2013, the company is dedicated to addressing global health challenges with its innovative products, which include AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences aims to establish itself as a leader in antiviral drug development through a commitment to scientific excellence and innovation.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.

Everest Medicines Limited is a clinical-stage biopharmaceutical company based in Shanghai, China, founded in 2017. The company focuses on licensing, developing, and commercializing innovative therapies to meet critical unmet medical needs in Greater China and other Asia Pacific markets. Its diverse portfolio includes eight clinical-stage drug candidates aimed at treating various conditions such as oncology, immunology, cardio-renal diseases, and infectious diseases. Everest Medicines aims to partner with innovative global companies to bring transformative pharmaceutical solutions to the Emerging Market, leveraging its expertise in clinical development, regulatory affairs, and business operations. The company's pipeline features several notable candidates, including Nefecon, EVER001, PTX-COVID19-B, and Eravacycline, among others.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, dedicated to the discovery and development of antibody therapeutics for cancer treatment. The company focuses on creating innovative immuno-oncology products that leverage the patient's immune system to effectively combat and eliminate cancer. Apexigen's therapeutic pipeline includes several candidates such as APX005M and APX201 for immuno-oncology, alongside APX003 and TRK-950 for oncology, as well as APX001 for inflammation and APX003 for ocular diseases. Additionally, the company has developed the APXiMAB platform, which facilitates the discovery of antibodies targeting novel immune system components. Founded in 2010, Apexigen aims to advance next-generation therapies that address significant unmet needs in cancer treatment.

Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that focuses on developing innovative CRISPR solutions for a variety of applications. The company offers DETECTR™, a diagnostic platform that identifies specific nucleic acids in samples, aiding in the detection of diseases such as bacterial infections, cancer, and viral infections. Additionally, Mammoth Biosciences provides CRISPR-Cas systems for genome editing, targeting therapeutic areas including immuno-oncology, autoimmune diseases, and liver diseases. By harnessing proprietary ultracompact proteins and leveraging advanced research and development, Mammoth aims to create affordable point-of-care tests and enhance diagnostics across healthcare, agriculture, and environmental monitoring. Co-founded by CRISPR pioneer Jennifer Doudna, the company has attracted significant investment from institutional and individual backers.

ReadCoor, Inc. is a technology company based in Cambridge, Massachusetts, specializing in the development and commercialization of a panomic spatial sequencing platform designed for researchers, clinicians, and pharmaceutical and diagnostics companies. The company's innovative platform, based on proprietary Fluorescent in situ Sequencing (FISSEQ) technology, enables the simultaneous detection and analysis of RNA, DNA, proteins, and therapeutics, while providing high-resolution three-dimensional imaging of tissue samples. This integration allows for comprehensive morphometric analysis and cellular localization, facilitating a deeper understanding of human biology and the advancement of therapeutic development. ReadCoor aims to support clients in accessing valuable clinical insights for treating various diseases, including cancer, infectious diseases, and neurological disorders. Established in 2016, ReadCoor operates as a subsidiary of 10x Genomics, Inc.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

Shanghai Kechow Pharma, Inc. is a biopharmaceutical company established in 2014 and headquartered in Shanghai, China. The company specializes in the discovery of targeted small molecule drugs, aiming to develop innovative therapies that improve upon existing treatments. KeChow Pharma collaborates with various partners to co-develop its drug candidates, emphasizing a commitment to advancing healthcare through novel therapeutic solutions.

Mynosys Cellular Devices is a global ophthalmic technology company dedicated to providing surgeons with innovative solutions that enable procedural excellence

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Hummingbird Bioscience is a biotechnology company specializing in the development of novel therapeutic antibodies for oncology and immuno-oncology indications. Utilizing systems biology approaches and proprietary computational platforms, they discover and engineer innovative biotherapeutics targeting challenging disease pathways with strong biological validation. Their pipeline includes lead assets HMBD-001 (anti-HER3) and HMBD-002 (anti-VISTA), both in cancer treatment. The company has formed strategic partnerships with Cancer Research UK and Amgen, and received a product development grant from the Cancer Prevention and Research Institute of Texas.

AnHeart Therapeutics is a biopharmaceutical company dedicated to improving the lives of cancer patients through the development of innovative pharmaceutical products. The company focuses on acquiring, developing, and commercializing novel therapies that enhance human health and quality of life. Its primary research product, AB-106, is an oral, highly selective small molecule inhibitor targeting ROS1 and NTRK, aimed at providing effective treatment options for cancer. By advancing its pipeline of precision therapies, AnHeart Therapeutics seeks to enable medical professionals to deliver significant medical advancements in oncology.

Baoyuan Biomedical is a clinical stage company focused on acquiring, developing and commercializing innovative drugs that improve human health and quality of life, and is committed to innovative drug development that does not meet clinical needs. Its main research product, AB-106, is an oral, highly selective ROS1/NTRK small molecule inhibitor.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

Luckin Coffee Inc. is a prominent coffee retailer in China, dedicated to providing freshly brewed drinks and pre-made food items. Founded in 2017 and headquartered in Xiamen, the company aims to establish itself as a leading coffee brand and service provider by utilizing high-quality raw materials and innovative business models. Luckin Coffee operates a variety of store formats, including pick-up stores, relax stores, and delivery kitchens, enabling a flexible customer experience. The company leverages technology through its mobile app and partnerships with third-party platforms to facilitate purchases. As of March 2019, it had over 2,370 locations across 28 cities in China. To enhance its offerings, Luckin sources Arabica coffee beans from various suppliers and collaborates with World Barista Champion teams to create its coffee recipes, while also providing a selection of juices and light meals.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on discovering and developing molecularly targeted, oral small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, China, Terns is dedicated to advancing a pipeline of innovative therapeutic candidates. Its notable products include TERN-101, a potent farnesoid X receptor agonist, and TERN-201, an amine oxidase inhibitor. The company leverages its expertise in disease biology and medicinal chemistry, along with a capital-efficient drug discovery model and robust clinical development capabilities, to address significant unmet medical needs in both China and the global market.

VelosBio, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-drug conjugates (ADCs) to treat various forms of cancer, including hematological cancers and solid tumors. The company's primary area of research centers on targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell-surface protein found in numerous tumors but absent in normal tissues, which makes it a promising target for cancer therapy. VelosBio's lead product, VLS-101, is a ROR1-directed ADC that has shown positive preclinical results and aims to provide new treatment options for patients. Founded in 2017, VelosBio operates under the umbrella of Merck & Co., Inc. as of December 2020, focusing on developing targeted therapies that can be administered alone or in combination with other treatments across a wide range of cancer types.

Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, dedicated to the discovery and development of antibody therapeutics for cancer treatment. The company focuses on creating innovative immuno-oncology products that leverage the patient's immune system to effectively combat and eliminate cancer. Apexigen's therapeutic pipeline includes several candidates such as APX005M and APX201 for immuno-oncology, alongside APX003 and TRK-950 for oncology, as well as APX001 for inflammation and APX003 for ocular diseases. Additionally, the company has developed the APXiMAB platform, which facilitates the discovery of antibodies targeting novel immune system components. Founded in 2010, Apexigen aims to advance next-generation therapies that address significant unmet needs in cancer treatment.

IMPACT Therapeutics, Inc. is a biotechnology company based in Shanghai, China, focused on discovering, developing, and commercializing innovative therapeutics for cancer and other life-threatening diseases. Founded in 2009, the company is dedicated to creating targeted anti-cancer treatments that leverage the concept of synthetic lethality. Its research and development efforts include a variety of novel drug projects, such as PARP inhibitors, Wee1 inhibitors, and agents targeting the Hedgehog pathway, among other DNA damage response (DDR) agents. Through its commitment to advancing targeted therapies, IMPACT Therapeutics aims to provide patients with new, effective treatment options for challenging medical conditions.

Omniome, Inc. is a biotechnology company based in San Diego, California, focused on developing a DNA sequencing platform that aims to deliver high accuracy in clinical sequencing. Founded in 2013, the company utilizes its proprietary Sequencing By Binding technology, which enhances nucleotide and DNA matching by harnessing the natural capabilities of polymerase. This innovative approach allows researchers to obtain accurate and rapid sequencing results at a lower cost, with the potential to significantly advance cancer diagnostics. Omniome is supported by prominent life sciences venture investors and is committed to becoming a trusted leader in the field of DNA sequencing.

Polares Medical S.A. is a medical device company based in Ecublens, Switzerland, with an additional office in Palo Alto, California. The company specializes in developing innovative solutions for patients suffering from mitral valve regurgitation. Its flagship product features a unique trans-catheter mitral valve system that facilitates the replacement of the posterior leaflet with a prosthetic leaflet. This design enables physicians to perform hemi-replacements of the mitral valve, improving coaptation with the native anterior leaflet and offering a less invasive treatment option for patients.

Mindstrong Health, established in 2013 and based in Mountain View, California, specializes in remote mental health care. It offers a digital therapeutic platform that combines AI-powered symptom tracking, evidence-based therapy, and psychiatry services. The platform provides structured, goal-oriented messaging sessions, covering areas such as cognitive behavioral therapy, psychoeducation, and crisis management. It aims to make mental health care more accessible and personalized, using passive data from human-computer interfaces to measure brain function and enable expert interventions.

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies. The company’s product pipeline includes several key candidates, such as AB928, a dual A2a/A2b adenosine receptor antagonist in Phase 1b/2 trials, and Zimberelimab, an anti-PD-1 monoclonal antibody currently being evaluated in Phase Ib studies. Additionally, Arcus is advancing AB154, an anti-TIGIT monoclonal antibody in Phase 2 trials, and AB680, a small-molecule CD73 inhibitor in Phase 1/1b studies for the treatment of metastatic pancreatic cancer. The company collaborates with Strata Oncology and AstraZeneca to enhance the development of its therapies and has strategic partnerships with firms like WuXi Biologics. Founded in 2015, Arcus aims to leverage emerging insights in immunology to create effective cancer treatments across various indications, including non-small cell lung cancer and pancreatic cancer.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

LevitasBio is focused on advancing cellular analytics through its innovative magnetic levitation technology. This platform, known as LeviCell, allows for the label-free purification of cells and nuclei, enabling researchers to analyze biological signatures without altering or damaging the samples. By overcoming traditional limitations in cellular analysis, LevitasBio's approach facilitates the study of high-value primary samples and sensitive cell types, regardless of their initial conditions. This capability provides significant advantages for scientists in the life sciences and healthcare sectors, allowing for a deeper and more accurate understanding of biological processes.

BCFoods is a food processing company that produces condiments, tomato paste, and other food ingredients from dehydrated fruits and vegetables. The company built an agricultural demonstration base to plant onion, tomato, and pepper crops and produce major types of vegetable and fruit pastes.

Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Pacific Palisades, California, focused on developing precision therapies for genetically-defined cancers. The company specializes in mTOR inhibitors, particularly ABI-009, aimed at treating patients with alterations in the TSC1 or TSC2 genes, where existing mTOR inhibitors have limitations in pharmacology, drug delivery, or safety. Aadi's primary focus is on providing transformational therapies for patients with ultra-rare cancers, such as perivascular epithelioid cell tumors (PEComa). Since its founding in 2011, Aadi Bioscience has aimed to address significant unmet medical needs in oncology and related therapeutic areas.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

Cirina is focused on developing innovative blood-plasma tests aimed at the early detection of deadly diseases, particularly cancer. By identifying these conditions at their earliest stages, the company enables patients to pursue curative treatments more effectively. Founded by Dennis Lo, a pioneer in plasma nucleic acid research, Cirina leverages advanced scientific insights to create testing products that facilitate timely monitoring and intervention. Headquartered in South San Francisco, California, the company is actively seeking to expand its team with top scientific and business talent to further its mission of empowering individuals to take proactive measures against devastating diseases.

ReadCoor, Inc. is a technology company based in Cambridge, Massachusetts, specializing in the development and commercialization of a panomic spatial sequencing platform designed for researchers, clinicians, and pharmaceutical and diagnostics companies. The company's innovative platform, based on proprietary Fluorescent in situ Sequencing (FISSEQ) technology, enables the simultaneous detection and analysis of RNA, DNA, proteins, and therapeutics, while providing high-resolution three-dimensional imaging of tissue samples. This integration allows for comprehensive morphometric analysis and cellular localization, facilitating a deeper understanding of human biology and the advancement of therapeutic development. ReadCoor aims to support clients in accessing valuable clinical insights for treating various diseases, including cancer, infectious diseases, and neurological disorders. Established in 2016, ReadCoor operates as a subsidiary of 10x Genomics, Inc.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in innovative catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a pre-tied 40mm suture loop for effective soft tissue closure through access points as small as 4.3mm, without leaving behind any metal, clips, or fabrics. This technology is designed to enhance patient safety by reducing the risk of thromboembolism. SentreHEART has obtained regulatory clearance for its devices for soft tissue ligation and approximation in the United States, Europe, and Canada.

BCFoods is a food processing company that produces condiments, tomato paste, and other food ingredients from dehydrated fruits and vegetables. The company built an agricultural demonstration base to plant onion, tomato, and pepper crops and produce major types of vegetable and fruit pastes.

AccuraGen Inc., founded in 2013 and located in Menlo Park, California, specializes in developing sequencing-based systems for detecting cancer mutations. The company has created a high-sensitivity technology that utilizes next-generation sequencing to identify cancer-related mutations in small amounts of circulating cell-free DNA (cfDNA) found in blood samples. This innovative approach addresses challenges in analyzing cfDNA by employing proprietary molecular biology techniques and computational algorithms that enhance error suppression. AccuraGen's system can amplify nanogram quantities of highly fragmented cfDNA over 1000-fold, allowing for the screening of a wide array of cancer-related genes with exceptional sensitivity, including at the single-digit molecular level. This technology aims to improve personalized cancer treatment by providing oncologists and clinicians with reliable molecular diagnostic capabilities.

GeneWeave Biosciences specializes in developing advanced diagnostic solutions to enhance clinical microbiology and address the challenges posed by drug-resistant infections. The company aims to support hospitals and physicians globally by enabling improved antibiotic stewardship and providing rapid determinations of optimal antibiotic therapy for critical bacterial infections. Utilizing its proprietary Smarticles™ technology, GeneWeave delivers homogeneous assays that can quickly measure bacterial drug resistance without the need for enrichment, culture, or extensive sample preparation, thereby streamlining the diagnostic process and contributing to better patient outcomes.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

GenapSys, Inc. develops innovative DNA sequencing technologies aimed at enhancing applied genomic testing and medical sequencing. Its primary product, the GenapSys Sequencer, utilizes a proprietary electrical-based detection method for single nucleotide incorporations, making it suitable for a wide range of applications, including research, gene editing, drug development, agriculture, forensics, and food testing. The sequencer is designed for versatility, allowing it to operate in various lab environments and automate clonal amplification. GenapSys is also focused on collaborating with local health agencies and researchers to facilitate rapid sequencing capabilities that can aid in controlling outbreaks. Its compact design enables deployment in diverse locations, such as hospitals and public transport hubs, for efficient virus sample analysis. Founded in 2010 and headquartered in Redwood City, California, GenapSys is committed to providing accessible and precise genetic testing solutions.

GeneWeave Biosciences specializes in developing advanced diagnostic solutions to enhance clinical microbiology and address the challenges posed by drug-resistant infections. The company aims to support hospitals and physicians globally by enabling improved antibiotic stewardship and providing rapid determinations of optimal antibiotic therapy for critical bacterial infections. Utilizing its proprietary Smarticles™ technology, GeneWeave delivers homogeneous assays that can quickly measure bacterial drug resistance without the need for enrichment, culture, or extensive sample preparation, thereby streamlining the diagnostic process and contributing to better patient outcomes.